NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries
(NASDAQ:ELAB), Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio's classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function. Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity. Phase […]